| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| ipilimumab nivolumab cco | 0.22 | 1 | 6952 | 48 | 24 |
| ipilimumab | 1.49 | 0.3 | 9794 | 15 | 10 |
| nivolumab | 1.55 | 0.9 | 9654 | 8 | 9 |
| cco | 1.9 | 0.1 | 1898 | 57 | 3 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| ipilimumab nivolumab cco | 0.32 | 0.1 | 2309 | 53 |
| ipilimumab nivolumab colon cancer | 1.53 | 0.6 | 9392 | 63 |
| ipilimumab nivolumab combination fda approval | 1.24 | 0.9 | 4982 | 2 |
| ipilimumab and nivolumab for colon cancer | 0.4 | 0.9 | 2291 | 74 |
| nivolumab ipilimumab lung cancer | 0.91 | 0.8 | 9671 | 80 |
| ipilimumab and nivolumab lung cancer | 0.06 | 0.5 | 8348 | 39 |
| nivolumab ipilimumab renal cancer | 1.87 | 1 | 9226 | 43 |
| ipilimumab + nivolumab | 0.89 | 1 | 3949 | 72 |
| nivolumab ipilimumab gastric cancer | 1.03 | 0.2 | 9882 | 88 |
| nivolumab ipilimumab small cell lung cancer | 0.86 | 0.3 | 1512 | 29 |
| ipilimumab and nivolumab patient information | 1 | 1 | 8927 | 48 |
| ipilimumab and nivolumab for melanoma | 0.41 | 0.8 | 6655 | 99 |
| nivolumab combined with ipilimumab | 1.95 | 0.9 | 4173 | 39 |
| nivolumab and ipilimumab sarcoma | 1.84 | 1 | 9114 | 78 |
| nivolumab ipilimumab hepatocellular carcinoma | 1.28 | 0.8 | 3169 | 24 |
